Filgrastim

Patients with cancer receiving myelosuppressive chemotherapy or induction and/or consolidation chemotherapy for AML Recommended starting dose is 5 mcg/kg/day by subcutaneous injection, short intravenous infusion (15 to 30 minutes), or continuous intravenous infusion. See Full Prescribing Information for recommended dosage adjustments and timing of administration Patients with cancer undergoing bone marrow transplantation: 10 mcg/kg/day given as an intravenous infusion no longer than 24 hours.

Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.

NYPOZI is contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim products or pegfilgrastim products. Patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim products or pegfilgrastim products

Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.

Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture. Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever and lung infiltrates or respiratory distress for ARDS. Discontinue NYPOZI in patients with ARDS. Serious allergic reactions, including anaphylaxis: Permanently discontinue NYPOZI in patients with serious allergic reactions. Fatal sickle cell crises: Discontinue NYPOZI if sickle cell crisis occurs. Glomerulonephritis: Evaluate and consider dose-reduction or interruption of NYPOZI if causality is likely.

Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.

The following serious adverse reactions are discussed in greater detail in other sections of the labeling: Splenic Rupture Acute Respiratory Distress Syndrome Serious Allergic Reactions Sickle Cell Disorders Glomerulonephritis Alveolar Hemorrhage and Hemoptysis Capillary Leak Syndrome Myelodysplastic Syndrome Acute Myeloid Leukemia Thrombocytopenia Leukocytosis Cutaneous Vasculitis Aortitis Most common adverse reactions in…

Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.

32 products from 28 makers in the NepalDoc medicine catalog use this generic:

Showing 30 of 32 catalog products. Search the full catalog in the app.

Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.

Storage: Store NYPOZI in the refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light.

Storage information from the U.S. FDA-approved label.